Integrum AB has unveiled a new global marketing strategy focused on its OPRA™ Implant System, showcased at AOPA's National Assembly in Orlando.

Integrum AB has identified errors in its Q1 2025/26 interim report, correcting figures for net sales and total expenses. This update will not affect KPIs.

Integrum AB reports strong sales growth and strategic partnerships in the first quarter of 2025, paving the way for future expansion despite operating losses.

Integrum AB has successfully obtained the top sponsorship title for the Global Collaborative Congress on Osseointegration for the next three years, enhancing its commitment to limb loss care.

Integrum AB has revealed a new performance-based compensation plan for its Acting CEO, Scott Flora, amidst a significant strategic transition.

A recent independent study highlights the significant advantages of Integrum's OPRA™ Implant System for amputees over two years, reinforcing its clinical benefits and improved quality of life.

Integrum AB collaborates with Intelerad to enhance surgical planning and patient care using innovative technology, ensuring better outcomes for amputees.

Integrum AB launches a pivotal service initiative aimed at enhancing support for its Axor™ II devices in the U.S. market, driving growth and customer satisfaction.